Bayer offers license opportunity

Bayer is seeking an exclusive licensee for its end-of-Phase I progestinagonist Bay 39-9624.

Bay 39-9624 is a novel non-steroidal progesterone receptor agonist which binds with high affinity to the progesterone receptor.

Bay 39-9624 demonstrates selectivity for the progesterone receptor greater than four orders of magnitude compared to the estrogen, androgen and glucocorticoid receptors. It has been proven to increase bone mineral density, bone formation rate and biochemical strength in rat models of post-menopausal osteoporosis. It was well-tolerated in three different species toxicity studies. In clinical Phase I single and multiple dose administration studies it was also well-tolerated.